Phase III randomised trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 2010; 28: 4575-4580.

Published: 4th April 2011

Authors: Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA et al.

Conclusion

This trial was stopped after inclusion of 2434 patients when refecoxib was withdrawn. The patients received the active drug for a median of seven months. At a median follow-up of nearly five years, rates of recurrence (hazard ratio 0.89, 95 per cent confidence interval 0.76 to 1.04, P=0.15) and overall survival (0.97, 0.81 to 1.16, P=0.75) were similar.

Pubmed Link

Your comments

0 Comments